Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Extends Antibody Deal With MorphoSys by Four Years

NEW YORK, June 26 (GenomeWeb News) - MorphoSys has expanded its existing therapeutic antibody collaboration with Novartis, and "in light" of the expansion" plans to update its financial guidance for 2006, the company said today.

 

The original three-year deal with Novartis, begun in 2004, will now go through May 2011, MorphoSys said. The company said it is "currently reviewing the status of its financial guidance 2006 and will provide an update latest by July 28, 2006, the presentation of its Q2 results [sic]."

 

Terms of the new agreement call for Novartis to increase the number of new therapeutic antibody projects annually --- "resulting in increased levels of ... funding."

 

In addition, "Novartis will have the option to receive access to the MorphoSys HuCAL GOLD library at an additional research site and will have access to a certain HuCAL affinity optimization technology at the HuCAL library installation sites at Novartis for optimization of non-therapeutic antibodies."

 

Finally, the agreement "provides for increased annual license fees, with commercial license fees, research and developmental milestones, and royalties on marketed antibody products remaining unchanged."

 

The original alliance was aimed at jointly developing new antibody-based therapeutics against a range of illnesses, MorphoSys said. As part of the deal Novartis took an equity stake in MorphoSys worth approximately €9 million, worth around $10.9 million at the time, and is today the company's largest shareholder.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.